A Comparison of HPLC-Thermal Energy Analysis and GC-Electron Capture Detection for Determining Isosorbide Dinitrate and Its Mononitrate Metabolites in Human Plasma

  • A. J. Woodward
  • P. A. Lewis
  • J. Maddock
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 14)


Isosorbide dinitrate (ISDN) is widely used for prophylactic treatment of angina pectoris and for the treatment of respiratory congestive heart failure. Sustained or controlled release preparations in a variety of dosage forms are becoming available. Thus there is considerable interest in the pharmacokinetics of the compound and the bioavailability of these new dosage forms. Further, the 5-mononitrate metabolite (IS5MN) has also been shown to be a potent anti-anginal substance, and thus more interest is being placed on determining this and the 2-mononitrate metabolite of ISDN (IS2MN).


Isosorbide Dinitrate Ethyl Acetate Solution Pentaerythritol Tetranitrate Control Release Preparation Simple Sample Preparation Procedure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosseel, M.T. & Bogaert, M.G. (1973) J. Pharm. Sci. 62, 754 – 758.CrossRefGoogle Scholar
  2. 2.
    as for 1. (1979) 68, 659–660.Google Scholar
  3. 3.
    Doyle, E., Chasseaud, L.F. & Taylor, T. (1980) Biopharm. Drug. Disp. 1, 141 – 147.CrossRefGoogle Scholar
  4. 4.
    Fung, H.L., McNiff, E.F., Ruggirello, D., Darke, A., Thadari, U. & Parker, J.D. (1981) Br. J. Pharmacol. 11, 579 – 589.Google Scholar
  5. 5.
    Maddock, J., Lewis, P.A., Woodward, A.J., Massey, P.R. & Kennedy, S. (1983) J. Chromatog. 272, 129 – 136.CrossRefGoogle Scholar


  1. Muskiet, F.A.J., Thomasson, C.G., Gerding, A.M., FremouwOttevangers, D.C., Nagel, G.T. & Wolthers, B.G. (1979) Clin. Chem. 25, 453–460Google Scholar
  2. Hegstrand, L.R. & Eichelman, B. (1981) J. Chromatog. 222, 107–111CrossRefGoogle Scholar
  3. Keller, R., Oke, A., Mefford, I. & Adam, R.N. (1976) Life Sci. 19, 995–1004CrossRefGoogle Scholar
  4. Baldessarini, R.J. & Fischer, J.E. (1978) Biochem. Pharmacol. 27, 621–626CrossRefGoogle Scholar
  5. Cross, A.J. & Joseph, M.H. (1981) Life Sci. 28, 499–505.CrossRefGoogle Scholar
  6. Lyness, W.H. (1982) Life Sci.. 31, 1435–1443CrossRefGoogle Scholar
  7. Holzebecher, M., Perry, R. A. & [.pers. comm. also] Ellenberger, H.A. (1982) J. For. Sci. 27, 715–717Google Scholar
  8. Krylov, A. I. & Khlebnikova, N. S. (1982) J. Chromatog.Google Scholar
  9. Trautmann, K.H. & Haef elf finger, P. (1981) J. High Resol. Chromatog. Chromatog. Comm. 4, 5–59.Google Scholar
  10. Masoud, A.N. & Krupski, D.M. (1980) J. Anal. Toxicol. 4, 305–310Google Scholar
  11. Pacifici, G.M., Placidi, G.F., Fornaro, P. & Goneni, R. (1983) Int. J. Clin. Pharm. Res. 3, 331–337Google Scholar
  12. Tanner, R. J. N., Martin, L. E. & Oxford, J. (1983) Anal. Proc. 20, 38–41Google Scholar
  13. Browne, T.R., van Langenhove, A., Costello, C.E., Biemann, K. & Greenblatt, D.J. (1984) Ther, Drug Monitoring 6, 3–9CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • A. J. Woodward
    • 1
  • P. A. Lewis
    • 1
  • J. Maddock
    • 1
  1. 1.Analytical DivisionSimbec Research Ltd.Mid GlamorganUK

Personalised recommendations